AAMU
ADAP

Amundi Asset Management US’s Adaptimmune Therapeutics ADAP Stock Holding History

Amundi Asset Management US’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-9
Closed – – 1626
2018
Q4 		$0 Sell
9
-5,900
-100% -$43.5K ﹤0.01% 1589
2018
Q3 		$80K Hold
5,909
– – ﹤0.01% 1536
2018
Q2 		$70K Hold
5,909
– – ﹤0.01% 1488
2018
Q1 		$66K Hold
5,909
– – ﹤0.01% 1465
2017
Q4 		$39K Buy
+5,909
New +$45.6K ﹤0.01% 1524

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Amundi Asset Management US's ADAP Position: Q1 2019 in Review

Amundi Asset Management US sold out of Adaptimmune Therapeutics (ADAP) in Q1 2019, closing a stake of 9 shares.

Amundi Asset Management US first reported a position in ADAP in Q4 2017 and held it in 5 quarters. The position peaked at $80K in Q3 2018. 68 funds tracked by Wall St. Rank hold ADAP as of Q1 2019.

  • Amundi Asset Management US reported no remaining Adaptimmune Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Amundi Asset Management US sold 9 Adaptimmune Therapeutics shares in Q1 2019.
  • Amundi Asset Management US first reported a position in Adaptimmune Therapeutics in Q4 2017 and held it in 5 quarters.
  • Amundi Asset Management US's Adaptimmune Therapeutics position peaked at $80K in Q3 2018.
  • 68 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2019.

Based on Amundi Asset Management US's 13F filing for Q1 2019, filed 13 May 2019.